19.51 USD
▼-0.23-1.17%
盘后 19.50 -0.05%
2026-11-19
市值
$2.21B
市盈率
—
EPS
-1.68
股息率
—
52 周区间
17.90 – 42.21
成交量
1.98M
Beta
0.14
目标价
50.86
52W 低 17.9052W 高 42.21
价格走势
公司简介
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartere...